In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment right until disease progression or even the participants are unable to tolerate the study drugs. - "Our study discovered the vital role from the KLF16/MYC regulatory axis https://douglasy110jue3.wikievia.com/user